BTIG Downgrades Athira Pharma to Neutral
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Thomas Shrader has downgraded Athira Pharma from Buy to Neutral, indicating a change in the analyst's outlook on the company's stock.
September 04, 2024 | 2:36 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BTIG analyst Thomas Shrader downgraded Athira Pharma from Buy to Neutral, suggesting a less optimistic view on the stock's potential performance.
The downgrade from Buy to Neutral by a reputable analyst like Thomas Shrader at BTIG suggests a shift in sentiment towards Athira Pharma, which could lead to a negative short-term impact on the stock price as investors may adjust their positions based on this new rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100